Controversies in ASSAY and drug development technologies: a focus on assessing irreproducibility.
Has the impact of irreproducibility on the discovery and development of drugs, as with global warming, metaphorically speaking, crept up on us as we slept? Or is the problem more an issue of heightened awareness? We currently find ourselves in a time when the impact of irreproducibility can easily be amplified by the combinatorial effect of our increasing reliance on advanced technologies and unrealistic expectations of how scientific truths unfold. How and why we got here is a topic that has been written on extensively (1-3) and is probably as complex as any other problem, given the dependence of science today on so many external forces. Through a series of questions, we asked members of our editorial board their opinions on scientific irreproducibility. They chose to answer the same questions from different levels, indicating the depth of the problem and perhaps where they each believe change for the better needs to begin. My thanks to the participants.
1 The Rockefeller University , New York, New York.
J Fraser
JF
Glickman
Thomas
T
Lundbäck
Andrew D
AD
Napper
Walter D
WD
Niles
Anton
A
Simeonov
C David
CD
Weaver
Hongwei Holly
HH
Yin
Guido J R
GJ
Zaman
Hiroyuki
H
Osada
D000818:Animals; D055808:Drug Discovery / Q000592:standards*; D057166:High-Throughput Screening Assays / Q000592:standards*; D006801:Humans; D015203:Reproducibility of Results